80178

Lithium; therapeutic drug monitoring

CPT code 80178 represents the quantitative assay of lithium in a patient's serum or plasma. Lithium is a primary mood-stabilizing medication utilized for the treatment and prophylaxis of bipolar disorder, including manic and depressive episodes. Because lithium has a notably narrow therapeutic index—meaning the range between a therapeutic dose and a toxic dose is very small—regular blood monitoring is clinically mandatory. The therapeutic range for lithium typically falls between 0.6 and 1.2 mEq/L for maintenance therapy, though higher levels may be sought during acute manic phases. Serum levels exceeding 1.5 mEq/L are generally considered toxic, which can lead to severe neurological and renal complications. The laboratory procedure for 80178 usually involves methodologies such as ion-selective electrode (ISE), flame photometry, or atomic absorption spectroscopy. For accurate results, blood should ideally be drawn at 'trough' levels, approximately 12 hours after the last dose was administered. The test evaluates whether the current dosage regimen is achieving the desired therapeutic effect while minimizing side effects. Clinicians also use this test to assess patient adherence to the medication regimen, as non-compliance is common in psychiatric populations. Furthermore, because lithium is excreted almost exclusively by the kidneys and can interfere with thyroid function, this assay is often performed alongside creatinine and thyroid-stimulating hormone (TSH) tests to monitor for systemic adverse effects.

Clinical Indications

  • Initial titration of lithium dosage in patients with bipolar disorder
  • Maintenance monitoring for patients on long-term lithium therapy
  • Suspected lithium toxicity (symptoms such as ataxia, confusion, or severe tremors)
  • Assessment of patient compliance with the prescribed medication regimen
  • Monitoring patients with changing renal function which may affect lithium clearance
  • Evaluation of drug-drug interactions (e.g., with NSAIDs, diuretics, or ACE inhibitors)
  • Recurrence of manic or depressive symptoms while on therapy
  • Monitoring during pregnancy due to physiological changes affecting volume of distribution

Procedure Steps

  1. Verification of the patient's identity and confirmation of the time of the last lithium dose (ideally 12 hours prior).
  2. Collection of venous blood via venipuncture using a standard collection tube (usually a red-top or gold-top serum separator tube).
  3. The specimen is allowed to clot if serum is required, followed by centrifugation to separate the serum or plasma from cellular components.
  4. The laboratory technician prepares the automated analyzer, which may use ion-selective electrode (ISE) technology or flame emission photometry.
  5. A standardized volume of the patient's serum is introduced into the analyzer for quantification.
  6. The analyzer measures the concentration of lithium ions against known standards.
  7. The results are recorded in milliequivalents per liter (mEq/L) or millimoles per liter (mmol/L).
  8. Laboratory staff review the result for accuracy and flag any values within the critical/toxic range for immediate provider notification.

Coding Guidelines

  • CPT 80178 should be used for the quantitative measurement of lithium only.
  • If the specimen collection is performed by the same provider/facility, the venipuncture (e.g., 36415) may be reported separately depending on payer policy.
  • This code belongs to the Therapeutic Drug Assay section; it is intended for monitoring a drug used for therapeutic purposes, not for forensic or screening purposes.
  • Repeat testing on the same day must be supported by medical necessity and may require modifiers such as -91.
  • Do not use 80178 if lithium is part of a multi-analyte panel unless specifically instructed; however, lithium is rarely bundled into standard chemistry panels.

Associated ICD-10 Codes